Hanmi Pharmaceutical is open to everyone exploring innovative technologies, including companies, scientists, and institutions.
Overview
Special
We are not merely seeking innovation that only increases corporate value. Hanmi's Open Innovation is focused on maximizing mutual synergy through cooperation between 'Innovation and Technology' rather than simply combining technology and capital. We strongly believe bolder and faster innovation can be achieved through cooperative models such as joint research, development, sales, licensing, and investment.
Sustainable
Since its establishment in 1973, Hanmi Pharmaceutical has grown into an R&D-centric company representing Korea. Open Innovation has always been at the center of Hanmi’s “Korean-style R&D,” from first generics to incrementally modified drugs, fixed-dose combinations, and innovative new drugs. The sustainability of Hanmi's R&D, leading the Korean biopharmaceutical industry, is “Open Innovation”.
Licensing
Licensing-out
-
2021
Oligopeptide
AffaMed Therapeutics
Luminate®
risuteganib
dry AMD
Greater China
-
2021
NCE
Aptose Biosciences
tuspetinib
HM43239, Myeloid Kinome Inhibitor, AML
WW
-
2021
Arthrex
HA injection
sodium hyaluronate
Joint Articular
US
-
2020
LAPS
MSD
efinopegdutide
HM12525A, GLP-1/Glucagon, MASH
WW (excluding Korea)
-
2019
Silanes
Amosartan Plus
amlodipin, losartan, chlorthalidon
Cardiovascular
Mexico
-
2019
Sanofi
Amosartan Q
amlodipin, losartan, rosuvastatin
Cardiovascular
CIS
-
2019
Silanes
Amosartan Q
amlodipin, losartan, rosuvastatin
Cardiovascular
Mexico
-
2019
Sanofi
Amosartan
amlodipine, losartan
Cardiovascular
CIS
-
2016
NCE
Genentech
belvarafenib
HM95573, pan-RAFi, Solid Tumor
WW (excluding Korea)
-
2015
MSD
Rosuzet
ezetimibe, rosuvasatin
Cardiovascular
WW
-
2015
LAPS
Sanofi
efpeglenatide
HM11260C, Exendin-4 analogue, Diabetes, Obesity
WW
-
2015
LAPS
Janssen
efinopegdutide
HM12525A, GLP-1/Glucagon, Diabetes, Obesity
WW (excluding Korea, and China)
-
2015
NCE
Zai Lab
olmutinib
HM61713, EGFRi, Solid Tumor
China
-
2015
NCE
Boehringer Ingelheim
olmutinib
HM61713, EGFRi, Solid Tumor
WW (excluding Korea, and China)
-
2015
NCE
Eli Lilly
poseltinib
HM71224, BTKi, Autoimmune
WW (excluding Korea, and Greater China)
-
2015
NCE
Spectrum (Assertio)
poziotinib
HM781-36B, pan-HERi, Solid Tumor
WW (excluding Korea and China)
-
2012
LAPS
Spectrum (Assertio)
Rolvedon
eflapegrastim
HM10460A, G-CSF, Neutropenia
WW (excluding Korea, China, and Japan)
-
2011
Orascovery Platform Technology
Athenex (C-Mer)
WW (excluding Korea)
-
2009
MSD
Amosartan
amlodipine, losartan
Cardiovascular
WW
-
2008
New Salt
ParaPro
Esomezol
esomeprazole strontum
New Salt, GI
US
-
1997
Microemulsion technology
Novartis
Exclusive
-
1989
Ceftriaxone technology
Roche
Exclusive
